{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052111","form_type":"8-K","ticker":null,"cik":"0001832168","company_name":"Longboard Pharmaceuticals, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.554922+00:00","generated_at":"2026-06-03T00:50:48.943661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Longboard Q1 2024: $321M cash; bexicaserin Phase 3 on track for YE 2024","bullets":["Cash, cash equivalents and investments of $321.0M as of March 31, 2024; cash runway into 2027.","Net proceeds of $226.5M from Jan 2024 follow-on offering (11.5M shares at $21.00) and $59.9M from private placement (2.85M non-voting shares at $21.00).","R&D expenses $13.2M (+54% YoY), primarily due to bexicaserin and LP659 trial costs.","Positive topline PACIFIC Study data for bexicaserin presented at AAN April 2024; global Phase 3 to start by YE 2024.","LP659 Phase 1 SAD topline data expected Q2 2024; PACIFIC open-label extension data in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052111","json":"https://secwatch.observer/filing/0000950170-24-052111.json","markdown":"https://secwatch.observer/filing/0000950170-24-052111.md","text":"https://secwatch.observer/filing/0000950170-24-052111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/0000950170-24-052111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/lbph-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:50:48.943661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed5994449140cbbc43b34f232af4fdefd87acb92","claim":"Longboard Pharmaceuticals, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"On May 2, 2024, Longboard Pharmaceuticals, Inc. (\"Longboard\") issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/0000950170-24-052111-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}